Bausch and Lomb has launched a novel daily nutritional supplement for dry eye in the United States after a successful clinical study.
The supplement, which features a proprietary blend of ingredients including lutein, zeaxanthin isomers, curcumin, and vitamin D3, will be marketed under the brand name Blink NutriTears.
Bausch and Lomb said the clinical study met both primary endpoints, a change in baseline at day 56 (eight weeks) in:
- tear production (Schirmer’s test), and
- in ocular symptoms measured by Ocular Surface Disease Index (OSDI) score.
The study also met secondary endpoints, showing statistically significant improvements in tear-film break-up time (TBUT), osmolarity, ocular surface health, and presence of an inflammatory marker.
Bausch and Lomb’s Executive Vice President, Research and Development and chief medical officer, Yehia Hashad said Blink NutriTears would “offer a novel nutritional option that can provide dry eye symptom relief in as little as two to four weeks”.
The announcement comes after the publication of the results of a prospective, randomised, double-blind, parallel, placebo-controlled study evaluating the efficacy and safety of NutriTears in 155 adult participants with mild dry eye symptoms.1
NutriTears was found to be well-tolerated. No serious adverse events were reported during the study period.
Reference
- Gioia, N., Gerson, J., Periman, L.m., et al., A novel multi-ingredient supplement significantly improves ocular symptoms severity and tear production in patients with dry eye disease: Results from a randomized, placebo-controlled clinical trial. Front. Ophthalmol. 2024;4. DOI: 10.3389/fopht.2024.1362113.
